Mary Scott
Oncology · Port Charlotte, FLNPI 1487852372
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $804, 2.4 times the $339 reported in 2021. That places this record below the midpoint for oncology clinicians in FL, where the typical reported total is $4,167.
Across 144 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$491
- Gilead$334
- Daiichi Sankyo Inc.$250
- Incyte Corporation$211
- Novartis$157
- AstraZeneca$130
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,845100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 28 | $491 |
| Gilead(2 entities) | 15 | $334 |
| Daiichi Sankyo Inc. | 9 | $250 |
| Incyte Corporation | 11 | $211 |
| Novartis | 8 | $157 |
| AstraZeneca(2 entities) | 7 | $130 |
| Johnson & Johnson | 7 | $114 |
| Pfizer | 5 | $104 |
| Seagen Inc. | 7 | $101 |
| Bristol Myers Squibb | 4 | $95 |
| Stemline Therapeutics Inc. | 3 | $82 |
| Beone Medicines USA, Inc. | 3 | $76 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $68 |
| Eisai Inc. | 3 | $63 |
| Array Biopharma Inc | 3 | $58 |
| Astellas Pharma US Inc | 3 | $47 |
| AbbVie | 2 | $46 |
| GSK | 1 | $34 |
| Lilly USA, LLC | 1 | $32 |
| Merck | 2 | $31 |
| Telix Pharmaceuticals | 1 | $25 |
| Beigene USA, Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| GE HealthCare | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Geron Corporation | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| G1 Therapeutics, Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Morphosys, US Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$2,845 in reported general payments places this provider in the 45th percentile of 24 oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $13,829 |
| EliquisApixaban | 12 | $7,654 |
| Letrozole | 92 | $2,831 |
| Anastrozole | 60 | $1,067 |
| Nystatin | 14 | $314 |
| Ondansetron OdtOndansetron | 17 | $249 |
| Acyclovir | 22 | $227 |
| Dexamethasone | 14 | $225 |
| Gabapentin | 22 | $176 |
| Prochlorperazine Maleate | 13 | $171 |
| Warfarin Sodium | 17 | $143 |
| Prednisone | 16 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $114 | $13,82911 claims |
| PfizerEliquis | $104 | $7,65412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 24 oncology providers in Florida.
Other oncology in Port Charlotte
- Sara BeelerTampa$337K
- Michelle RampersadSebring$34K
- Janell VerkadenOrmond Beach$19K
- Kimberly TopeTampa$16K
- Aaron DohenySt Petersburg$14K
- Naima Vera-SommersTampa$11K
- Amber AlbaughLecanto$9K
- Natalie GessnerClearwater$8K
- Melissa BlandfordHudson$6K
- Glenda KaminskiLakeland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.